Grace Therapeutics Inc(GRCE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.18 | Insider Own | 18.68% | Shs Outstand | 21.0M | Perf Week | -5.56% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 31.11% | Insider Trans | 10.95% | Shs Float | 17.1M | Perf Month | -11.79% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.15 | Inst Own | 32.32% | Short Float | 9.84% | Perf Quarter | -10.1% |
| Income | -0.02B | P/S | - | EPS this Y | -43.62% | Inst Trans | -4.42% | Short Ratio | 10.03 | Perf Half Y | -10.95% |
| Sales | 0.00B | P/B | 0.63 | EPS next 5Y | - | ROA | -33.74% | Short Interest | 1.68M | Perf YTD | -45.95% |
| Book/sh | 2.96 | P/C | 2.86 | EPS past 3/5Y | 56.43% 43.17% | ROE | -36.19% | 52W High | -63.9% ($5.18) | Perf Year | -40.63% |
| Cash/sh | 0.65 | P/FCF | - | Sales past 3/5Y | - | ROIC | -41.94% | 52W Low | 11.98% ($1.67) | Perf 3Y | -22.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -43.6% | Gross Margin | - | Volatility(W/M) | 7.15% 5.6% | Perf 5Y | -81.34% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | -97.22% |
| Dividend Ex-Date | - | Quick Ratio | 11.47 | EPS Q/Q | -333.11% | Profit Margin | - | RSI (14) | 39.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.47 | Sales Q/Q | - | SMA20 | -5.79% ($1.98) | Beta | 0.43 | Target Price | $6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -10.35% ($2.09) | Rel Volume | 0.66 | Prev Close | $1.81 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -603.79% - | SMA200 | -34.22% ($2.84) | Avg Volume(3M) | 0.17M | Price | $1.87 |
| IPO | 2011/5/6 | Option/Short | Yes/Yes | Trades | 325 | Volume | 110,543 | Change | 3.31% |
A US late-stage clinical biotech company developing innovative precision medicines to treat complications from brain hemorrhages. Through its proprietary GTx-104, the company is focused on reducing the side effects of existing treatments and improving survival rates and quality of life for patients with cerebrovascular diseases.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded less than usual. That is 66% of its average volume.
GRCE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -43.6% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 32.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% It ranks #435 of 594 in the industry
Based on market cap of $39M.
TIL#433 Instil Bio Inc $40M PER - 
DWTX#434 Dogwood Therapeutics Inc $39M PER - GRCE#435 Grace Therapeutics Inc $39M PER - 
VERU#436 Veru Inc $39M PER - 
ALDX#437 Aldeyra Therapeutics Inc $39M PER - 
FAQ
What kind of company is GRCE?
GRCE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GRCE?
The market cap of GRCE is approximately $39M, ranking 4,966 within its sector.
What is the 52-week high and low for GRCE?
GRCE has recorded a 52-week high of $5.18 and a low of $1.67.
